Market Access FDA’s treatment of China-developed drugs spurs demands for m... China’s emergence as an R&D powerhouse means that the country is quickly adding a number of drug candidates to the global pipeline.
Market Access Is it time to rethink electronic prescribing in the US? It is a fact of life that most – if not all – patients will require some form of prescription medication during their lifetime.
Market Access Combination pricing: access to the future of oncology treatm... Combination therapies are fast becoming the cornerstone of cancer treatment: not just in the UK, but across the world.
Market Access Orphan drugs' financial success raises questions R&D into orphan drugs is growing alongside the number of approved treatments, providing treatments for rare diseases that previously did not have any.
Market Access Closing the digital expectation gap in pharma Jan Deman is Takeda’s head of digital customer experience for Europe and Canada. But he’d prefer not to refer to what he does as “innovation”.
Market Access How do we make patient centricity a reality? For years, the subject of fostering direct connections with patients has been highlighted by notable figures across the healthcare and life sciences industries as a key feature to be explor
News Relief for AZ as Truqap hits the spot in prostate cancer After a disappointing result with Truqap in triple-negative breast cancer, AstraZeneca chalks up a win in prostate cancer
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends